ARCHIVES

The Raghavan Experiment: With $500 Million to Draw On, An Iconoclast Invents Rational Care for a Gigantic System

This article is from The Cancer Letter archive.

Vol. 39 No. 01 | January 4, 2013

Download PDF Visit The Full Archive

Related Articles

OMB Orders NCI to Cut 12 Percent Until Final budget Is Approved; Grants Being Renegotiated

December 4, 1981

FDA Approves Iressa For Third-Line Treatment Of Non-Small Cell Lung Cancer

May 9, 2003

Gynecologic Oncology Group To Conduct Phase III Trial of Xyotax For Ovarian Cancer

April 30, 2004

NCI Cuts Back Directed Research Funds, Encourages Investigator – Initiated Grants

February 23, 1996

Advisors’ Report On Intramural Program To Recommend Restructuring

April 14, 1995

Avastin Phase III Trial Meets Endpoint: PFS in Platinum-Sensitive Ovarian Cancer

February 25, 2011